United Therapeutics authorized a new share repurchase program of up to $2.0 billion to be executed over the next year. The buyback is a material capital-allocation move that should be modestly EPS-accretive, supportive of the equity and likely to improve investor sentiment in the near term.
United Therapeutics authorized a new share repurchase program of up to $2.0 billion to be executed over the next year. The buyback is a material capital-allocation move that should be modestly EPS-accretive, supportive of the equity and likely to improve investor sentiment in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
